This article has been updated to clarify that Myriad Genetics Q3 hereditary cancer testing revenues were largely impacted by pricing concessions to payors, and in small part due to an out-of-network decision by Anthem.
360Dx Premium gives you: ✔ Full site access ✔ Interest-based email alerts ✔ Access to archives
Never miss another important industry story.
Try 360Dx Premium now.
You may already have institutional access!
Check if I qualify.
Already a 360Dx or GenomeWeb Premium member?Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.